Inhibrx Current ratio
Mi az Inhibrx Current ratio?
A Current ratio az Inhibrx, Inc. - 6.20
Mi a Current ratio meghatározása?
A jelenlegi arány likviditási mutató, amely azt méri, hogy a vállalatnak elegendő forrása van-e a rövid távú kötelezettségek teljesítéséhez.
The current ratio is an indication of a company's liquidity and measures the capability to meet a company's short-term obligations. It compares a firm's current assets to its current liabilities, and is expressed as current assets divided by current liabilities. The ratio is only useful when two companies are compared within industry because inter industry business operations differ substantially. To determine liquidity, the current ratio is not as helpful as the quick ratio, because it includes all those assets that may not be easily liquidated, like prepaid expenses and inventory.
Acceptable current ratios vary from industry to industry. In many cases an investor would consider a high current ratio to be better than a low current ratio, because a high current ratio indicates that the company is more likely to pay the investor back. Large current ratios are not always a good sign for investors. If the company's current ratio is too high it may indicate that the company is not efficiently using its current assets or its short-term financing facilities. If current liabilities exceed current assets the current ratio will be less than 1. A current ratio of less than 1 indicates that the company may have problems meeting its short-term obligations.
Some types of businesses can operate with a current ratio of less than one however. If inventory turns into cash much more rapidly than the accounts payable become due, then the firm's current ratio can comfortably remain less than one. Inventory is valued at the cost of acquiring it and the firm intends to sell the inventory for more than this cost. The sale will therefore generate substantially more cash than the value of inventory on the balance sheet. Low current ratios can also be justified for businesses that can collect cash from customers long before they need to pay their suppliers.
Current ratio a Health Care szektor a NASDAQ-on cégekben a Inhibrx -hoz képest
Mit csinál Inhibrx?
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
current ratio -hoz hasonló cégek Inhibrx
- Geotech nak Current ratio 6.19 van
- Tiltrenew Fpo Nzx nak Current ratio 6.19 van
- Shriram City Union Finance nak Current ratio 6.19 van
- Lightspeed POS nak Current ratio 6.19 van
- Lightspeed POS nak Current ratio 6.19 van
- Osisko Mining nak Current ratio 6.20 van
- Inhibrx nak Current ratio 6.20 van
- Dolly Varden Silver nak Current ratio 6.20 van
- Beijing Hotgen Biotech Co nak Current ratio 6.20 van
- Kismet Resources nak Current ratio 6.20 van
- Host Hotels & Resorts nak Current ratio 6.20 van
- Host Hotels & Resorts Inc nak Current ratio 6.20 van
- Fastned B.V nak Current ratio 6.20 van